Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Men and non-pregnant women, at least 18 years of age~* Antiretroviral treatment-naïve; defined as no current or previous exposure to \> 1 week of an antiretroviral drug~* Plasma HIV-1 RNA ≥ 1000 copies/mL~* CD4 T-cell count \> 200 cells/mm3~Exclusion Criteria:~* Resistance or partial resistance to any study drug determined by tests at Screening~* Current or historical genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to EFV, TDF, FTC, Protease Inhibitors~* Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV)~* Blood tests that indicate normal liver function~* Hemoglobin \< 8.0 g/dL, platelets \< 50,000 cells/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: BMS-955176 60 mg + TDF/FTC (Type: EXPERIMENTAL): BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
- Arm 2: BMS-955176 120 mg + TDF/FTC (Type: EXPERIMENTAL): BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
- Arm 3: BMS-955176 180 mg + TDF/FTC (Type: EXPERIMENTAL): BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
- Arm 4: EFV + TDF/FTC (Type: ACTIVE_COMPARATOR): BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).